Generic placeholder image

Current Bioinformatics


ISSN (Print): 1574-8936
ISSN (Online): 2212-392X

Research Article

Bioinformatics Analysis of Quantitative PCR and Reverse Transcription PCR in Detecting HCV RNA

Author(s): Wei Liu, Xiwen Jiang, Yue Liu and Qingsong Ma*

Volume 14 , Issue 5 , 2019

Page: [400 - 405] Pages: 6

DOI: 10.2174/1574893613666180703103328

Price: $65


Objective: This research aimed to make comparisons of sensitivity and specificity between Quantitative real Time Polymerase Chain Reaction (Q-PCR) and Reverse Transcription PCR (RT-PCR) in detecting the ribonucleic acid (RNA) expression levels of Hepatitis C Virus (HCV).

Methods: 121 patients suffering from hepatitis C and 98 healthy participants with normal liver functions were identified. The venous blood collections were carried out, were subjected to detect the expression levels of HCV RNA via Q-PCR and RT-PCR. And then, the data obtained from these above two detection methods were compared, including the sensitivity and specificity.

Results: In terms of Q-PCR, the positive rate of HCV RNA was 72.16%, which was significantly higher when compared with 55.26% of RT-PCR. After statistical analysis, the difference between them was statistically significant (P<0.05). Among the healthy participants, 4 cases were false positive by means of RT-PCR, there was the possibility of missed diagnosis when the samples were evaluated by Q-PCR.

Conclusion: The Q-PCR detection technology performed well in testing HCV, with pretty high sensitivity and specificity. Nevertheless, the false negative results obtained from Q-PCR could not be avoided. In clinical practice, these above two detection methods should be referred to, in order to avoid missed diagnosis.

Keywords: Hepatitis C virus, ribonucleic acid, quantitative real time polymerase chain reaction, reverse transcription polymerase chain reaction, liver cirrhosis, hepatocellular carcinoma.

Graphical Abstract
Uchiyama N, Kamakura H, Masada S, et al. Chemical analysis of counterfeit hepatitis C drug found in Japan. Yakugaku Zasshi 2017; 137(10): 1265-76.
Ladino M, Pedraza F, Roth D. Opportunities for treatment of the hepatitis C virus-infected patient with chronic kidney disease. World J Hepatol 2017; 9(19): 833-9.
Jeffrey AW, Huang Y, de Boer WB, et al. Improved Hepascore in hepatitis C predicts reversal in risk of adverse outcome. World J Hepatol 2017; 9(19): 850-6.
Muñoz de Rueda P, Fuentes Rodríguez JM, Quiles Pérez R, et al. Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment. World J Gastroenterol 2017; 23(25): 4538-47.
Grewal P, Sanghera R. Hepatitis B and C viruses and biologics. Skin Therapy Lett 2017; 22(4): 7-9.
Xu HT, Colby-Germinario SP, Hassounah SA, et al. Evaluation of Sofosbuvir (β-D-2′-deoxy-2′-α-fluoro-2′-β-C-methyluridine) as an inhibitor of dengue virus replication. Sci Rep 2017; 7(1): 6345.
Wang Z, Gao Y, Zhang C, et al. Quinolinate phosphoribosyl-transferase is an antiviral host factor against hepatitis C virus infection. Sci Rep 2017; 7(1): 5876.
Tanaka Y, Iwasaki M, Murata-Hirai K, et al. Anti-tumor activity and immunotherapeutic potential of a bisphosphonate prodrug. Sci Rep 2017; 7(1): 5987.
Stelma F, de Niet A, Sinnige MJ, et al. Human intrahepatic CD69+ CD8+ T cells have a tissue resident memory T cell phenotype with reduced cytolytic capacity. Sci Rep 2017; 7(1): 6172.
Madhvi A, Hingane S, Srivastav R, et al. A screen for novel hepatitis C virus RdRp inhibitor identifies a broad-spectrum antiviral compound. Sci Rep 2017; 7(1): 5816.
Luong TTD, Tran GVQ, Shin DJ, Lim YS, Hwang SB, Hepatitis C. hepatitis C virus exploits death receptor 6-mediated signaling pathway to facilitate viral propagation. Sci Rep 2017; 7(1): 6445.
Chen J, Zhang Z, Wang N, et al. Role of HDAC9-FoxO1 axis in the transcriptional program associated with hepatic gluconeo-genesis. Sci Rep 2017; 7(1): 6102.
Wijarnpreecha K, Thongprayoon C, Panjawatanan P, Phatharacharukul P, Ungprasert P. Hepatitis C virus infection and risk of osteoporosis: A meta-analysis. Saudi J Gastroenterol 2017; 23(4): 216-21.
Al-Busafi SA, Omar H. Towards supporting greater and lower cost access to direct acting antiviral treatment for hepatitis C for all patients. Saudi J Gastroenterol 2017; 23(4): 263-4.
WHO Guidelines on Hepatitis B and C Testing 2017, 2017.
Huang MY, Chung CH, Chang WK, et al. The role of thia-zolidinediones in hepatocellular carcinoma risk reduction: A population-based cohort study in Taiwan. Am J Cancer Res 2017; 7(7): 1606-16.
Vieira-Castro ACM, Oliveira LCM. Impact of alcohol consumption among patients in hepatitis C virus treatment. Arq Gastroenterol 2017; 54(3): 232-7.
Gorzoni ML, Aguado MRV, Pires SL, Faria LFC. Compulsory notification at skilled nursing facilities. Rev Assoc Med Bras (1992) 2017. 63(5): 447-51.
Stelzl E, Haas B, Bauer B, et al. First identification of a recombinant form of hepatitis C virus in Austrian patients by full-genome next generation sequencing. PLoS One 2017; 12(7): e0181273.
Sabet S, George MA, El-Shorbagy HM, et al. Gelatin nanoparticles enhance delivery of hepatitis C virus recombinant NS2 gene. PLoS One 2017; 12(7): e0181723.
Russelli G, Pizzillo P, Iannolo G, et al. HCV replication in gastrointestinal mucosa: Potential extra-hepatic viral reservoir and possible role in HCV infection recurrence after liver transplantation. PLoS One 2017; 12(7): e0181683.
Merdan M, Bekiryazici Z, Kesemen T, Khaniyev T. Deterministic stability and random behavior of a Hepatitis C model. PLoS One 2017; 12(7): e0181571.
Hughes MG Jr, Tucker WW, Reddy S, et al. Rate of hepatitis C viral clearance by human livers in human patients: Liver transplantation modeling primary infection and implications for studying entry inhibition. PLoS One 2017; 12(7): e0180719.
Liu Y, Liu Y, Zou X, Chen W, Ling L. Trends and factors in human immunodeficiency virus and/or hepatitis C virus testing and infection among injection drug users newly entering methadone maintenance treatment in Guangdong Province, China 2006-2013: a consecutive cross sectional study. BMJ Open 2017; 7(7): e015524.
Lu M, Chacra W, Rabin D, et al. Validity of an automated algo-rithm using diagnosis and procedure codes to identify decom-pensated cirrhosis using electronic health records. Clin Epidemiol 2017; 9: 369-76.
McEwan P, Webster S, Ward T, Brenner M, Kalsekar A, Yuan Y. Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus. Cost Eff Resour Alloc 2017; 15: 15.
Bernuth S, Grimm D, Vollmar J, et al. Efficacy and safety of direct-acting antiviral therapy in previous hard-to-treat patients with recurrent hepatitis C virus infection after liver transplantation: a real-world cohort. Drug Des Devel Ther 2017; 11: 2131-8.
Rychlik W, Spencer WJ, Rhoads RE. Optimization of the annealing temperature for DNA amplification in vitro. Nucleic Acids Res 1990; 18(21): 6409-12.
Joseph S, David WR. Molecular cloning: A Laboratory. Manual 3rd ed.. 2001.
Ferri C, Colaci M, Fallahi P, Ferrari SM, Antonelli A, Giuggioli D. Thyroid involvement in hepatitis C virus-infected patients with/without mixed cryoglobulinemia. Front Endocrinol 2017; 8: 159.
Son K, Nguyen TTT, Choi JW, et al. Rad51 Interacts with Non-structural 3 protein of hepatitis C Virus and regulates viral production. Front Microbiol 2017; 8: 1249.
Jovanovic MR, Miljatovic A, Puskas L, Kapor S, Puskas DL. Does the strategy of risk group testing for hepatitis C hit the target? Front Pharmacol 2017; 8: 437.
Des Jarlais DC. Harm reduction in the USA: the research perspective and an archive to David Purchase. Harm Reduct J 2017; 14(1): 51.
Alouani I, Fihmi N, Zizi N, Dikhaye S. Dermatomyositis revealing both a metastatic linitis plastica and hepatitis C virus infection. Indian J Dermatol Venereol Leprol 2017; 83(5): 606-9.
Ribeiro Barbosa J, Sousa Bezerra C, Carvalho-Costa FA, et al. Cross-sectional study to determine the prevalence of hepatitis B and C virus infection in high risk groups in the northeast region of brazil. Int J Environ Res Public Health 2017; 14(7): 14.
Bruno G, Saracino A, Scudeller L, et al. HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ? Int J Infect Dis 2017; 62: 64-71.
Agrawal B, Singh S, Gupta N, Li W, Vedi S, Kumar R. Unsolved puzzles surrounding HCV immunity: Heterologous immunity adds another dimension. Int J Mol Sci 2017; 18(8): 18.
Shaukat AA, Zar A, Zuhaid M, Afridi SS. Correlation of deviance in arterial oxygenation with severity of chronic liver disease. J Ayub Med Coll Abbottabad 2016; 28(2): 331-6.
Pirro M, Bianconi V, Francisci D, et al. Hepatitis C virus and proprotein convertase subtilisin/kexin type 9: A detrimental interaction to increase viral infectivity and disrupt lipid metabolism. J Cell Mol Med 2017; 21(12): 3150-61.
Kah J, Koh S, Volz T, et al. Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection. J Clin Invest 2017; 127(8): 3177-88.
Soto-Ramirez LE. World hepatitis day. Fighting hepatitis C in Latin America and the Caribbean; an urgent call. J Int AIDS Soc 2017; 20(1): 22183.
Ito M, Sun S, Fukuhara T, et al. Development of hepatoma-derived, bidirectional oval-like cells as a model to study host interactions with hepatitis C virus during differentiation. Oncotarget 2017; 8(33): 53899-915.

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy